International Journal of Hematology-Oncology and Stem Cell Research最新文献_第10页

Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease rossai Dorfman病合并脑实质内、髓内和脑膜内疾病的全身性和颅脊髓性疾病

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-10-01 DOI: 10.18502/ijhoscr.v15i4.7482

Yi Li, E. Sloan, A. Bollen, D. Solomon, P. Theodosopoulos, S. Cha

引用次数: 1

Neuroblastoma Cell Death Induced by eEF1A2 Knockdown Is Possibly Mediated by the Inhibition of Akt and mTOR Phosphorylation eEF1A2敲低诱导神经母细胞瘤细胞死亡可能是通过抑制Akt和mTOR磷酸化介导的

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-10-01 DOI: 10.18502/ijhoscr.v15i4.7477

Kawinthra Khwanraj, P. Dharmasaroja

{"title":"Neuroblastoma Cell Death Induced by eEF1A2 Knockdown Is Possibly Mediated by the Inhibition of Akt and mTOR Phosphorylation","authors":"Kawinthra Khwanraj, P. Dharmasaroja","doi":"10.18502/ijhoscr.v15i4.7477","DOIUrl":"https://doi.org/10.18502/ijhoscr.v15i4.7477","url":null,"abstract":"Background The protein kinase B/mammalian target of the rapamycin (Akt/mTOR) pathway is one of the most potent prosurvival signaling cascades that is constitutively active in neuroblastoma. The eukaryotic translation elongation factor-1, alpha-2 (eEF1A2) protein has been found to activate the Akt/mTOR pathway. However, there is a lack of data on the role of eEF1A2 in neuroblastoma. The present study investigated the effect of eEF1A2 silencing on the viability of neuroblastoma cells and its possible signaling. Materials and Methods: Human SH-SY5Y neuroblastoma cells were transfected with small interfering RNA (siRNA) against eEF1A2. After 48 h of transfection, cell viability was assessed using an MTT assay. The mRNA expression of p53, Bax, Bcl-2, caspase-3 and members of the phosphoinositide 3-kinases (PI3K)/Akt/mTOR pathway was determined using quantitative real-time RT-PCR (qRT-PCR). The protein expression of Akt and mTOR was measured using Western blot analysis. Results: eEF1A2 knockdown significantly decreased the viability of neuroblastoma cells. No significant changes were observed on the expression of p53, Bax/Bcl-2 ratio, and caspase-3 mRNAs; however, the upregulated trends were noted for the p53 and Bax/Bcl-2 ratio. eEF1A2 knockdown significantly inhibited the phosphorylation of both Akt and mTOR. Almost all of the class I (PIK3CA, PIK3CB, and PIK3CD) and all of the class II PI3K genes were slightly increased in tumor cells with eEF1A2 knockdown. In addition, a slightly decreased expression of the Akt2, mTORC1, and mTORC2 was observed. Conclusion: eEF1A2 knockdown induced neuroblastoma cell death, in part through the inhibition of Akt and mTOR, suggesting a potential role of eEF1A2 as a molecular target for neuroblastoma therapy.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"60 1","pages":"221 - 229"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90206932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

RHD Genotyping of Rh-Negative and Weak D Phenotype among Blood Donors in Southeast Iran 伊朗东南部献血者rh阴性和弱D表型的RHD基因分型

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-10-01 DOI: 10.18502/ijhoscr.v15i4.7476

Younes Sadeghi-Bojd, N. Amirizadeh, A. Oodi

{"title":"RHD Genotyping of Rh-Negative and Weak D Phenotype among Blood Donors in Southeast Iran","authors":"Younes Sadeghi-Bojd, N. Amirizadeh, A. Oodi","doi":"10.18502/ijhoscr.v15i4.7476","DOIUrl":"https://doi.org/10.18502/ijhoscr.v15i4.7476","url":null,"abstract":"Background: The D antigen is a subset of Rh blood group antigens involved in the hemolytic disease of the newborn [HDFN] and hemolytic transfusion reaction [HTR]. The hybrid Rhesus box that was created after RH gene deletion, was known as a mechanism of the Rh-negative phenotype. Hybrid marker identification is used to confirm the deletion of the RHD gene and to determine zygosity. This study aims to detect this marker in Rh-negative and weak D phenotype blood donors of the southeast of Iran. Materials and Methods: The molecular analysis of the hybrid Rhesus box was performed on the 200 Rh-negative blood donors in Sistan and Baluchestan province, southeast Iran. The presence of alleles responsible for the D variants was assessed by DNA sequencing in 26 weak D phenotype donors. Results: Of the 200 Rh-negative blood samples, 198 samples were homozygous (99%), and two samples were heterozygous (1%). Heterozygous samples had RHD*01N.73 allele and the RHD*01N.18 allele. Of the 26 samples with weak D phenotype, 16 partial DLO (61%), 4 partial DBT1 (15.3%), 2 partial DV type 2 (7.7%), 1 weak D type 1, 1 weak D type 4.2.3, 1weak D type 105 and 1 RHD (S103P) (4%) were determined. Conclusion: Since RHD gene deletion is the main mechanism of the Rh-negativity in Sistan and Baluchestan provinces, a hybrid Rhesus box marker can be used in resolving RhD typing discrepancies by RHD genotyping methods.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"13 1","pages":"213 - 220"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90396131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Hodgkin Variant of Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review 慢性淋巴细胞白血病(CLL)中Richter转化的霍奇金变异体:一例说白性病例报告及文献复习

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-10-01 DOI: 10.18502/ijhoscr.v15i4.7480

N. Gupta, Aditi Mittal, R. Duggal, T. Dadu, A. Agarwal, A. Handoo

{"title":"Hodgkin Variant of Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL): An Illustrative Case Report and Literature Review","authors":"N. Gupta, Aditi Mittal, R. Duggal, T. Dadu, A. Agarwal, A. Handoo","doi":"10.18502/ijhoscr.v15i4.7480","DOIUrl":"https://doi.org/10.18502/ijhoscr.v15i4.7480","url":null,"abstract":"Hodgkin lymphoma variant of Richter’s transformation (HL-RT) is a rare event, occurring in < 1% chronic lymphocytic leukemia (CLL) cases, of which, in < 10% cases, HL is the first finding leading to a diagnosis of CLL that co-exists simultaneously. Here we report a 60 years old male patient who presented with an outside diagnosis of lymphocyte-rich classical HL. On evaluation, he had only B-symptoms in the form of low-grade fever and weight loss. Peripheral smear revealed mild leukocytosis with an absolute lymphocytosis and a few smudge cells. Bone marrow (BM) aspirate and biopsy exhibited diffuse infiltration by a small cell, low grade, Non-Hodgkin’s lymphoma with no immunohistochemical evidence of HL. Flow cytometry performed on BM was consistent with classical immunoprofile of CLL. Meanwhile the lymph node received for review revealed diffuse effacement of nodal architecture by small mature lymphocytes with immunoprofile of CLL expressing CD20, CD5, and CD23. Interspersed between these cells, were a few eosinophils along with classical Reed Sternberg cells, expressing CD30, MUM-1, CD15, and dim PAX-5, with a surrounding rosette of T-Cells highlighted by CD3 and PD-1 and negative for CD45, CD20, and EBV immunohistochemistry. Fluorodeoxyglucose positron emission tomography (FDG-PET) scan revealed hepatosplenomegaly with multiple supra/infra diaphragmatic lymph nodes. So, a final diagnosis of HL-RT in CLL was considered. The patient is currently doing well after the first cycle of ABVD chemotherapy. HL-RT occurring in CLL is a rare event with heterogeneous clinical presentation, morphology, clonal origin, disease course, prognostic features, and survival.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"28 1","pages":"249 - 254"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86856507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Prolonged Thrombin Time in Asymptomatic Patient with Hypo Dysfibrogememia Tucson 低纤维异常血症无症状患者凝血酶时间的延长

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-08-24 DOI: 10.14302/issn.2372-6601.jhor-21-3903

S. Katakkar

{"title":"Prolonged Thrombin Time in Asymptomatic Patient with Hypo Dysfibrogememia Tucson","authors":"S. Katakkar","doi":"10.14302/issn.2372-6601.jhor-21-3903","DOIUrl":"https://doi.org/10.14302/issn.2372-6601.jhor-21-3903","url":null,"abstract":"A 61 years female patient with known diagnosis of the breast cancer in remission for more than 10 years has Renaud’s disease. During her work up for lupus and lupus anticoagulant which both were negative a prolonged thrombin time was noted which was done by mistake. She has no history of bleeding or thrombosis and last recent surgery was 5 years ago for spinal stenosis and was uncomplicated. Her clinical examination is normal without evidence of any spontaneous bruises but colder hands. The thrombin time was greater than 125 seconds on two different occasions and correction of it by addition of normal plasma was down to 56 seconds and was thus incomplete. Her prothrombin time and PTT were normal and there was no evidence of FDP or D-Dimers. There was no evidence of circulating heparins. The fibrinogen level was normal. The para proteinmia was excluded by normal serum protein electrophoresis and by immunofixation . Thus it is felt that this patient has dysfibrinogenemia or hypo dysfibrinogenemia without bleeding or thrombotic complication. The literature review shows approximately 55% of dysfibrinogenemia patients do not have bleeding or thrombotic complications.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"1622 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72432888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determination of Tumor Size and Hounsfield Unit/Electron Density Values in Three Different CT Scans for Lung SBRT Planning 三种不同CT扫描对肺SBRT规划的肿瘤大小和Hounsfield单位/电子密度值的测定

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-07-31 DOI: 10.4999/uhod.214054

A. Okumus

引用次数: 0

Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience 帕唑帕尼治疗晚期非透明肾细胞癌患者的生存结局:回顾性单机构经验

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-07-31 DOI: 10.4999/uhod.215146

O. Aktepe

引用次数: 0

Anxiety, Insomnia and Pandemic Awareness of Cancer Patients Receiving Chemotherapy During the COVID-19 Pandemic Period 2019冠状病毒病疫情期间癌症化疗患者的焦虑、失眠与流行意识

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-07-31 DOI: 10.4999/uhod.214677

S. Esen

{"title":"Anxiety, Insomnia and Pandemic Awareness of Cancer Patients Receiving Chemotherapy During the COVID-19 Pandemic Period","authors":"S. Esen","doi":"10.4999/uhod.214677","DOIUrl":"https://doi.org/10.4999/uhod.214677","url":null,"abstract":"The emergence of COVID-19 pandemic caused a global public health problem. In this article, anxiety and insomnia rates of cancer patients who received chemotherapy during COVID-19 outbreak period were determined. In addition, patients' information and opinions about COVID-19 were discussed. The study included 218 cancer patients who apply to outpatient chemotherapy clinic between May-June 2020, aged 18 and over, who were receiving chemotherapy. Generalized Anxiety Disorder and Insomnia Severity Index questionnaire forms were given to fill the patients to evaluate their anxiety and insomnia levels. We also prepared 12 additional questions about the knowledge and perceptions of COVID-19. Seventy eight (35.8%) patients had anxiety and 106 (48.6%) had insomnia. The rate of whole patients with severe anxiety was 1.8% and with severe insomnia was 2.8%. There was a statistically significant relationship between tumor localization and anxiety (p=0.006). Anxiety scores also increased with the increase in insomnia scores (p< 0.001). Eighty three percent of our patients wore face masks in any environment where they were in contact with people, and 84.9% believed in the protection of the face mask. To the authors'knowledge, this is the first study to examine the anxiety and insomnia rates of the cancer patients receiving chemotherapy in COVID-19 pandemic. The uncertainty of the COVID-19 pandemic process can further increase anxiety and insomnia rates. Patients should be evaluated psychosocially both in the pandemic process and after. Correcting these misperception should be targe-ted in information campaigns, information by clinicians to their patients, and media coverage.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"106 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73364907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Clinical Course of Covid-19 in Hematological Disorders Covid-19在血液系统疾病中的临床病程

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-07-31 DOI: 10.4999/uhod.215014

M. H. Atay, M. Okuyucu, Y. T. Gullu, N. T. Tuna, H. Bilek, E. Tanyel, O. Terzi, M. Turgut

{"title":"Clinical Course of Covid-19 in Hematological Disorders","authors":"M. H. Atay, M. Okuyucu, Y. T. Gullu, N. T. Tuna, H. Bilek, E. Tanyel, O. Terzi, M. Turgut","doi":"10.4999/uhod.215014","DOIUrl":"https://doi.org/10.4999/uhod.215014","url":null,"abstract":"Hematology patients are extremely vulnerable to COVID-19 infection due to the immunosuppression arising from the direct effect of the disease and the medicines administered. Our purpose is to analyze the results of the patients that both have a hematological disease and receive treatment for COVID-19 infection in our hospital. Four hundred COVID-19 positive patients that received inpatient treatment between March 12, 2020 and October 1, 2020 in our center and got a diagnosis by using real -time polymerase chain reaction (RT-PCR) test were scanned retrospectively. Eighty one patients were included in the study. Nineteen patients had a hematological disease;62 had a chronic disease but didn't have a hematological disease. We found that the group with hematological disease had a high level of ferritin (p= 0.0001). While the use of steroids in COVID-19 treatments is more frequent in the group with hematological disease (p= 0.01), the use of LMWH (low molecular weight heparin) is more frequent in the group with no hematological diseases (p= 0.02). Intensive care treatment and mechanical ventilatory support were required more for the patients with hematological disease than the others (p= 0.03. p= 0.008). While the mortality rate is 42.1% in the patients with hematological disease, it is 9.7% in the patients with chronic disease (p= 0.003). In cox regression analysis, the study found that hematological diseases (HR: 4.02, 95% CI: 1.7-1844.5, p= 0.02), cardiac diseases (HR: 2.28, 95% CI: 1.2-77.9, p= 0.03), and intensive care treatment (HR: 4.60, 95% CI: 3.1-3115.0, p= 0.009) are significant risk factors. Hematological patients infected with COVID-19 have a more severe and mortal clinical manifestation than the patients with other chronical disease.","PeriodicalId":38991,"journal":{"name":"International Journal of Hematology-Oncology and Stem Cell Research","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86624783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center Experience 直肠癌新辅助放疗:单中心经验

International Journal of Hematology-Oncology and Stem Cell Research Pub Date : 2021-07-31 DOI: 10.4999/uhod.214936

B. Tilki

引用次数: 0